^
Association details:
Biomarker:PD-L1 negative
Cancer:Melanoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Published date:
09/18/2020
Excerpt:
In the 853 patients with PD-L1–positive tumors, the 3-year RFS rate was 65.3% (95% CI, 60.5% to 69.7%) in the pembrolizumab group and 46.4% (95% CI, 41.5% to 51.1%) in the placebo group (HR stratified by stage, 0.57; 99% CI, 0.43 to 0.74; P < .001; Fig 2B). Pembrolizumab was also consistently effective in the 116 patients with PD-L1–negative tumors, with the 3-year RFS rate being 56.9% (95% CI, 43.2% to 68.4%) in the pembrolizumab group and 33.3% (95% CI, 20.4% to 46.6%) in the placebo group. In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent across subgroups.
DOI:
10.1200/JCO.20.02110 Journal of Clinical Oncology
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Excerpt:
...The exception to this is patients with NSCLC who test negative for PD-L1 expression or are unevaluable for PD-L1 expression must have received prior platinum-based chemotherapy for entry into Cohort 2....
Trial ID: